Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Frederick Lundry Locke, Armin Ghobadi, Caron A. Jacobson, Eric D. Jacobsen, David Bernard Miklos, Lazaros J. Lekakis, Ira Braunschweig, Olalekan O. Oluwole, Yi Lin, Tanya Siddiqi, Abhinav Deol, Patrick Michael Reagan, Umar Farooq, Adrian Bot, Yizhou Jiang, John M. Rossi, Allen Xue, William Y. Go, Sattva Swarup Neelapu
Institutions: Moffitt Cancer Center, Washington University in St. Louis, Dana-Farber Cancer Institute, Stanford Medicine, Stanford University, University of Miami Health System, Albert Einstein College of Medicine, Montefiore Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Mayo Clinic, City Of Hope National Medical Center, City of Hope, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Rochester Medicine, University of Iowa, The University of Texas MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889856695